RHPAPPA2 PROTEIN FOR THE TREATMENT OF GROWTH PROBLEMS AND THE IMPROVEMENT OF BONE QUALITY.

Description

This technology proposes a novel therapy based on the recombinant human protein rhPAPPA2, designed to improve childhood growth and bone quality in patients with low bioavailability of insulin-like growth factor 1 (IGF-1).

This invention is particularly relevant for the treatment of patients with mutations in the PAPPA2 gene, who present with short stature and impaired bone mineralization, offering an innovative and targeted therapeutic alternative.

Advantages

A) Modulation of Bone Metabolism

1. Treatment with rhPAPPA2 promotes a balance between bone formation and resorption processes.

2. It contributes to improved bone composition and bone mineral density.

B) Application in Specific Growth Disorders

1. An innovative therapeutic approach for the treatment and prevention of Dauber-Argente short stature (DSS) in prepubertal girls with PAPPA2 mutations.

Uses and Applications

The invention falls within the biotechnology and biomedical sector, with the following main applications:

1. Use of rhPAPPA2 as a medicament for the treatment of growth disorders in children.

2. Integration into personalized medicine programs for rare disorders associated with PAPPA2 mutations.

3. Technology transfer to biotechnology companies interested in the development of innovative pediatric therapies.

4. Comercialización mediante acuerdos de licencia, codesarrollo o cesión de derechos de explotación.

Keywords

Sectors

Areas

Applicants

UNIVERSIDAD DE MÁLAGA, SERVICIO ANDALUZ DE SALUD (SAS), UAM. UNIVERSIDAD AUTÓNOMA DE MADRID, HOSPITAL NIÑO JESÚS DE MADRID

Inventors

JUAN SUAREZ PEREZ, JESÚS ARGENTE OLIVER, MARÍA DEL MAR FERNÁNDEZ ARJONA, ANTONIO JESÚS LOPEZ GAMBERO, JULIE ANN CHOWEN, FERNANDO RODRÍGUEZ DE FONSECA, LETICIA OLGA RUBIO LAMIA, PATRICIA RIVERA GONZÁLEZ

Filing Date

22/12/2025 

Protection Level: National (Spain)

Processing Status: Spanish protection application in priority period